<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846686</url>
  </required_header>
  <id_info>
    <org_study_id>IRBN622021/CHUSTE</org_study_id>
    <nct_id>NCT04846686</nct_id>
  </id_info>
  <brief_title>Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.</brief_title>
  <acronym>PRE-EVE</acronym>
  <official_title>Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commissariat A L'energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible&#xD;
      for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current&#xD;
      concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation&#xD;
      results from an imbalance of angiogenic factors.&#xD;
&#xD;
      A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor)&#xD;
      also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE.&#xD;
      EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2&#xD;
      team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA&#xD;
      Grenoble) demonstrated its key role in the control of key processes in placental development&#xD;
      and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is&#xD;
      directly involved in the development of Pre-Eclampsia. Few studies have evaluated the&#xD;
      expression of EG-VEGF in the human placenta.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry</measure>
    <time_frame>At delivery</time_frame>
    <description>Measured by placenta pathological examination (immunohistochemistry technical).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry</measure>
    <time_frame>At delivery</time_frame>
    <description>Measured by placenta pathological examination (immunohistochemistry technical).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry</measure>
    <time_frame>At delivery</time_frame>
    <description>Measured by placenta pathological examination (immunohistochemistry technical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry</measure>
    <time_frame>At delivery</time_frame>
    <description>Measured by placenta pathological examination (immunohistochemistry technical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry</measure>
    <time_frame>At delivery</time_frame>
    <description>Measured by placenta pathological examination (immunohistochemistry technical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).</measure>
    <time_frame>At delivery</time_frame>
    <description>Measured by placenta pathological examination (immunohistochemistry technical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of at least one chronic maternal pathologies describe below</measure>
    <time_frame>At delivery</time_frame>
    <description>diabetes, hypertension, kidney disease, Systemic Lupus Erythematosus (SLE), antiphospholipid syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetric history</measure>
    <time_frame>At delivery</time_frame>
    <description>Pre-Eclampsia (PE) and intra uterine growth retardation (IUGR), term of onset and severity of Pre-Eclampsia (PE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of an anticoagulant treatment</measure>
    <time_frame>At delivery</time_frame>
    <description>treatment by aspirin or Heparin or low molecular weight heparins (LMWH)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>preeclampsia group</arm_group_label>
    <description>25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized.&#xD;
Placenta pathological examination will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized.&#xD;
Placenta pathological examination will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placenta pathological examination</intervention_name>
    <description>a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>preeclampsia group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      placental&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have given birth by cesarean section at the maternity University Hospital&#xD;
        Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne&#xD;
        University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who have given birth by cesarean section at the maternity University&#xD;
             Hospital Saint Etienne and all underwent a placenta pathological examination at the&#xD;
             Saint Etienne University Hospital.&#xD;
&#xD;
          -  For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia&#xD;
&#xD;
          -  For the control group: patient who had a normal pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who gave birth naturally&#xD;
&#xD;
          -  Underage patients or under guardianship&#xD;
&#xD;
          -  Patients who do not speak or read French&#xD;
&#xD;
          -  Childbirth under X&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiphaine BARJAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiphaine BARJAT, MD</last_name>
    <phone>(0)477828383</phone>
    <phone_ext>+33</phone_ext>
    <email>tiphaine.barjat@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline CHAULEUR, MD PhD</last_name>
    <email>celine.chauleur@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Tiphaine BARJAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>EG-VEGF</keyword>
  <keyword>Prokineticin</keyword>
  <keyword>cesarean</keyword>
  <keyword>placenta pathological examination</keyword>
  <keyword>pregnancy</keyword>
  <keyword>PROK1 receptor</keyword>
  <keyword>PROKR2 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

